Fecal Microbiota Transplantation for Primary Clostridium difficile Infection

粪便细菌疗法 艰难梭菌 医学 粪便 临床终点 甲硝唑 微生物学 艰难梭菌 感染控制 肠道菌群 临床试验 内科学 胃肠病学 移植 免疫学 重症监护医学 抗生素 生物
作者
Frederik Emil Juul,Kjetil Garborg,Michael Bretthauer,Hilde Skudal,Mari Nanna Øines,Håvard Wiig,Øystein Rose,Birgitte Seip,J. Thomas LaMont,Tore Midtvedt,Jørgen Valeur,Mette Kalager,Øyvind Holme,Lise Mørkved Helsingen,Magnus Løberg,Hans‐Olov Adami
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:378 (26): 2535-2536 被引量:201
标识
DOI:10.1056/nejmc1803103
摘要

To the Editor: Clostridium difficile infection is a major health problem. 1 Antibiotic treatment is associated with a considerable rate of recurrence of infection and is related to the emergence of antibiotic-resistant bacteria.Recently, fecal microbiota transplantation has been shown to be effective in the treatment of recurrent C. difficile infection. 2 We undertook a proof-of-concept trial (ClinicalTrials.govnumber, NCT02301000) to evaluate the use of fecal microbiota transplantation as treatment for primary C. difficile infection.The trial began on November 25, 2014, and the first patient underwent randomization on February 22, 2015.From February 2015 through November 2017, at six hospitals in Norway, we randomly assigned 21 adult patients with acute C. difficile infection (≥3 loose stools per day and a positive C. difficile stool test) who had not had previous C. difficile infection to recommended treatment in Norway 3 (oral metronidazole at a dose of 400 mg three times a day for 10 days) or fecal microbiota transplantation (one 60-ml enema of anaerobically cultivated human intestinal microbiota) (see the Supplementary Appendix, available with the full text of this letter at NEJM.org). 4,5 Achim Biotherapeutics, which provided the fecal microbiota suspension free of charge to the investigators for the purpose of the trial, had no role in the design, conduct, or analyses of the trial.The protocol, available at NEJM.org, was approved by the institutional review board, and all patients provided written informed consent.The primary end point was clinical cure (firm stool consistency or ≤3 bowel movements per day) with no evidence of recurrence of C. difficile infection when the patient was evaluated at day 70 by an assessor who was unaware of the treatment assignment.Secondary end points were
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JIASHOUSHOU完成签到,获得积分10
刚刚
一颗煤炭完成签到 ,获得积分10
刚刚
Cipher完成签到 ,获得积分10
1秒前
脑洞疼应助LIUYONG采纳,获得10
1秒前
可乐完成签到,获得积分10
1秒前
2秒前
koukousang完成签到,获得积分10
3秒前
乐乐应助张无缺采纳,获得10
4秒前
三三完成签到,获得积分10
4秒前
平常荷花完成签到 ,获得积分10
6秒前
量子星尘发布了新的文献求助10
7秒前
阿胡发布了新的文献求助30
7秒前
水晶李完成签到 ,获得积分10
8秒前
脑洞疼应助静静子采纳,获得100
11秒前
新年好完成签到,获得积分10
12秒前
爆米花应助Michelle采纳,获得10
15秒前
15秒前
LYSM应助晴栀采纳,获得10
16秒前
Bean完成签到,获得积分10
16秒前
16秒前
16秒前
幸福妙柏完成签到 ,获得积分10
17秒前
汕头凯奇完成签到,获得积分10
18秒前
aoba完成签到 ,获得积分10
19秒前
潇洒的平松完成签到,获得积分10
20秒前
qwer完成签到,获得积分10
20秒前
fduqyy发布了新的文献求助10
20秒前
csu_zs完成签到,获得积分10
20秒前
20秒前
LILYpig完成签到 ,获得积分10
21秒前
文静醉易完成签到,获得积分10
21秒前
无聊的翠芙完成签到,获得积分10
22秒前
zhangxuhns完成签到,获得积分10
23秒前
大力哈密瓜完成签到,获得积分10
23秒前
无花果应助碧蓝碧凡采纳,获得10
24秒前
25秒前
26秒前
28秒前
蒋50完成签到,获得积分10
28秒前
不爱喝纯牛奶完成签到,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029